Outlook Therapeutics · ONS-5010 · Aug → Dec 2025
What changed between the FDA's August and December 2025 letters?
The deficiency stayed the same, as Outlook reported it. What was new: the FDA's view of the mechanistic and natural history data added in November, and, the company said, no word on what kind of evidence would be acceptable.
EphemerisX Research · Published · 6 source documents · 1 min read
Short answer
As Outlook reported them, both letters cite the same single deficiency and make the same recommendation, confirmatory evidence of efficacy. The December letter adds that the mechanistic and natural history data submitted in November did not alter the review's conclusion; the company says the FDA did not indicate what type of confirmatory evidence would be acceptable.
What the evidence shows
The quotable pages of the two letters carry the same instructions. August: A resubmission must fully address all the deficiencies listed in this letter
FDA · Aug 27, 2025 · p. 3. December: A resubmission must fully address all the deficiencies listed in this letter
FDA · Dec 30, 2025 · p. 3. Both say of the proposed brand name that it was found conditionally acceptable pending approval of the application in the current review cycle
FDA · Dec 30, 2025 · p. 2.
The company's own description of its case also shifted between the two letters: see the comparison below, and How did Outlook's description of NORSE EIGHT change?
The first page of each FDA letter, which states the deficiency, has no text layer in the published PDF and is not quoted here.
What changed
The letter's reason, August (press release): because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted
8-K · Sep 2, 2025. December (press release): the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion
8-K · Jan 2, 2026, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application
8-K · Jan 2, 2026.
What the company expected. Before the second letter: we believe this resubmission will resolve the outstanding issue
8-K · Nov 3, 2025. After it: We are disappointed and disagree with this decision
8-K · Jan 2, 2026.
The company's basis for approval. August 14, 2025: the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials
8-K · Aug 14, 2025. December 2025: the complete data set for NORSE TWO, combined with the data from the other NORSE clinical trials
8-K · Jan 2, 2026.
The letters' signature pages are dated 08/27/2025
FDA · Aug 27, 2025 · p. 5 and 12/30/2025
FDA · Dec 30, 2025 · p. 5.
Follow the thread
- What did the FDA's August 2025 letter object to?The August letter's reason, as reported
- What did Outlook say came out of its September 2025 meeting with the FDA?“Will resolve the outstanding issue”
- How did evidence the FDA said did not alter its conclusion come to establish substantial evidence?Mechanistic and natural history data “does not alter”
- Did the FDA ask Outlook for another clinical trial, or for confirmatory evidence?“Has not indicated what type” of evidence
This investigation connects to
- How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Replimune
- When is one trial enough? How the FDA weighed the evidence in three programsCross-investigation · Comparable evidence · with Aldeyra Therapeutics, Replimune
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed August 14, 2025
Outlook Therapeutics believes that the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.Open at the source →
FDA Complete Response Letter, August 27, 2025 · page 3
A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.Open at the source →
Outlook Therapeutics Form 8-K, filed September 2, 2025
The CRL included only one deficiency, for a lack of substantial evidence of effectiveness. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness.Open at the source →
Outlook Therapeutics Form 8-K, filed November 3, 2025
Based on our productive meeting with the FDA in September, we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025.Open at the source →
FDA Complete Response Letter, December 30, 2025 · page 2
This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to all the application deficiencies that have been identified in this letter.Open at the source →
FDA Complete Response Letter, December 30, 2025 · page 3
A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.Open at the source →
Outlook Therapeutics Form 8-K, filed January 2, 2026
In the CRL, the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application, however the FDA has not indicated what type of confirmatory evidence would be acceptable.Open at the source →
Outlook Therapeutics Form 8-K, filed January 2, 2026
We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States.Open at the source →
Outlook Therapeutics Form 8-K, filed January 2, 2026
Outlook Therapeutics continues to believe that the complete data set for NORSE TWO, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.Open at the source →